APA

Mease P. J., Smolen J. S., Behrens F., Nash P., Liu Leage S., Li L., Tahir H., Gooderham M., Krishnan E., Liu-Seifert H., Emery P., Pillai S. G. & Helliwell P. S. (20200420). A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. : Annals of the rheumatic diseases.

Chicago

Mease Philip J, Smolen Josef S, Behrens Frank, Nash Peter, Liu Leage Soyi, Li Lingnan, Tahir Hasan, Gooderham Melinda, Krishnan Eswar, Liu-Seifert Hong, Emery Paul, Pillai Sreekumar G and Helliwell Philip S. 20200420. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. : Annals of the rheumatic diseases.

Harvard

Mease P. J., Smolen J. S., Behrens F., Nash P., Liu Leage S., Li L., Tahir H., Gooderham M., Krishnan E., Liu-Seifert H., Emery P., Pillai S. G. and Helliwell P. S. (20200420). A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. : Annals of the rheumatic diseases.

MLA

Mease Philip J, Smolen Josef S, Behrens Frank, Nash Peter, Liu Leage Soyi, Li Lingnan, Tahir Hasan, Gooderham Melinda, Krishnan Eswar, Liu-Seifert Hong, Emery Paul, Pillai Sreekumar G and Helliwell Philip S. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. : Annals of the rheumatic diseases. 20200420.